6 October 2015
EMA/PDCO/614334/2015
Procedure Management and Committees Support Division

Paediatric Committee (PDCO)

Draft agenda for the meeting on 7-9 October 2015

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

7 October 2015, 08:30- 19:00, room 2A

8 October 2015, 08:30- 19:00, room 2A

9 October 2015, 08:30- 13:00, room 2A

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PDCO plenary session to be held 07-09 October 2015. See October 2015 PDCO minutes (to be published post November 2015 PDCO meeting).

1.2. Adoption of agenda

PDCO agenda for 7-9 October 2015.

1.3. Adoption of the minutes

PDCO minutes for 9-11 September 2015.

2. Opinions

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.4. Opinions on Re-examinations

2.5. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure January 2016 for Nomination of Rapporteur and Peer reviewer

Action: For adoption

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Action: For adoption

4.3. Nominations for other activities

Action: For adoption

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

Note: Products proposed for presentation / discussion during the PDCO plenary are flagged in the Annex A. The briefing packages for SAWP procedures are included in column 'S' of the table.

6. Discussion on the applicability of class waivers

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

None.

8. Annual reports on deferrals

8.1.1. Adalimumab – Humira - EMEA-000366-PIP02-09

AbbVie Limited

Difficulties progressing the PIP? Yes

Action: For information

8.1.2. Adalimumab – Humira - EMEA-000366-PIP04-12

AbbVie Limited

Difficulties progressing the PIP? No

Action: For information

8.1.3. Adalimumab – Humira - EMEA-000366-PIP05-12

AbbVie Limited

Difficulties progressing the PIP? Yes

Action: For information

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. Debriefing on White Paper DG discussions and proposal for future steps of the PDCO

PDCO member: Koenraad Norga

Action: For discussion

9.1.2. PDCO ORGAM dates for 2016

Action: For adoption

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Action: For information

9.2.2. Article 31 on Fusafungine: Pharmacovigilance Risk Assessment Committee (PRAC) List of questions to the Paediatric Committee (PDCO)

Action: For discussion

9.2.3. Draft Scientific Guideline on Post-authorisation efficacy studies (PAES)

Action: For adoption

9.2.4. Announcement of Review and Learning Meeting to be organised in Netherlands on 1-3 June 2016

PDCO Member Hendrik van den Berg

Action: For information

9.2.5. Report from the 'European Medicines Agency workshop on extrapolation across age groups' held on 30 September 2015

Action: For information

9.3. Coordination with EMA Working Parties / Working Groups / Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Jacqueline Carleer

Action: For information

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Action: For information

9.3.3. Draft mandate, objectives and rules of procedure for PDCO Formulation Working Group and PDCO Non-Clinical Working Group

PDCO members: Brian Aylward and Jacqueline Carleer

Action: For adoption

9.3.4. Inventory of paediatric therapeutic needs – gastroenterology

PDCO member: Birka Lehmann

Action: For adoption

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

None.

9.4.2. Involvement of young people in PDCO's activities

Action: For discussion

9.5. Cooperation with International Regulators

9.5.1. Report from the 'European Forum for Good Clinical Practice (EFGCP)/ Drug Information Association (DIA)/European Medicines Agency (EMA) Annual Conference on Better Medicines for Children' held on 1-2 October 2015

PDCO Chairperson: Dirk Mentzer

Action: For information

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

None

9.7. PDCO work plan

None

9.8. Planning and reporting

None

9.9. PDCO ORGAM

None

9.10. Others

9.10.1. Use of comparators in trials - lessons learned during project 'Global Research in Paediatrics' (GRIP)

Action: For discussion

9.10.2. Update of the European Commission on the economic study project

Action: For information

10. Any other business

10.1. None.

11. Breakout sessions

11.1.1. Paediatric oncology

Action: For discussion on Thursday, 19:00 - 19:30, room 2E

11.1.2. Neonatology

Action: For discussion on Thursday, 19:00 - 19:30, room 2C

12. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/